These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18389598)

  • 41. [PATHOGENIC AND PATHOPHYSIOLOGIC STUDY OF ASCITES IN CIRRHOTIC PATIENTS, AND ESPECIALLY IN NORTH AFRICAN SPLENOMEGALIC CIRRHOSES].
    HAEFFNER A
    Maroc Med; 1963 Sep; 42():673-8. PubMed ID: 14054470
    [No Abstract]   [Full Text] [Related]  

  • 42. [Clinical aspects and physiopathology of functional renal insufficiency in hepatic cirrhosis].
    García Puig J; Mateos Antón F; Gaspar G; Fernández Capitán MC; Gil Aguado A
    Rev Clin Esp; 1982 Oct; 167(1):1-3. PubMed ID: 7178578
    [No Abstract]   [Full Text] [Related]  

  • 43. [Influence of Na supplement and limitation on blood PRA, AII, ALD and renal function in patients with liver cirrhosis].
    Gu XB; Chen HK; Zhu YF; Pei H; Liu XY
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):370. PubMed ID: 15225438
    [No Abstract]   [Full Text] [Related]  

  • 44. [Changes in renal excretion of amino acids in patients after portasystemic anastomoses].
    Nádvorníková H; Schück O; Vosmík J; Tomková D; Teplan V
    Vnitr Lek; 1985 Mar; 31(3):276-84. PubMed ID: 4036016
    [No Abstract]   [Full Text] [Related]  

  • 45. Apparent inappropriate anti-diuretic hormone secretion in cirrhosis of the liver.
    Danovitch SH; Shora W; Berkman PM
    Med Ann Dist Columbia; 1971 Jan; 40(1):16-8 passim. PubMed ID: 5276266
    [No Abstract]   [Full Text] [Related]  

  • 46. Renal function impairment in patients with cirrhosis having pulmonary hypertension.
    Kalambokis GN; Fotopoulos A; Pappas K; Tsianos EV
    Angiology; 2011 Oct; 62(7):585-7. PubMed ID: 21422055
    [No Abstract]   [Full Text] [Related]  

  • 47. [Activity of the nephron in liver cirrhosis].
    Ortiz de Landazuri E; Arroyo JL; Bueno J; Conchillo F; Purroy A
    Rev Esp Enferm Apar Dig; 1970 Jan; 30(1):47-60. PubMed ID: 5436786
    [No Abstract]   [Full Text] [Related]  

  • 48. [Clinical course of liver cirrhosis. Clinical-statistical studies on 400 patients].
    Gigglberger H
    Acta Hepatosplenol; 1969; 16(1):34-46. PubMed ID: 5800608
    [No Abstract]   [Full Text] [Related]  

  • 49. Cirrhosis with portal hypertension and ascites in kwashiorkor (a clinical-pathological study).
    Hanafy MM; Hassanein EA; el-Khateeb S
    J Trop Pediatr (1967); 1968 Mar; 14(1):3-7. PubMed ID: 5300889
    [No Abstract]   [Full Text] [Related]  

  • 50. [Effect of zinc deficiency on effectiveness of the treatment of liver encephalopathy in patients with liver cirrhoses].
    Shaposhnikova NA; Drozdov VN; Petrakov AV; Sil'vestrova SIu
    Eksp Klin Gastroenterol; 2007; (5):46-50, 164. PubMed ID: 18389597
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Studies of renal function in patients with compensated hepatic cirrhosis].
    Oancea R
    Med Interna (Bucur); 1971 Oct; 23(10):1239-48. PubMed ID: 5127134
    [No Abstract]   [Full Text] [Related]  

  • 52. [Functional renal status in patients with hypothyroidism].
    Nikolaeva AV; Pimenov LT
    Klin Med (Mosk); 1999; 77(10):21-2. PubMed ID: 10635648
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Residual accessory spleen after splenectomy in liver cirrhosis with portal hypertension.
    Mishin I
    Rom J Gastroenterol; 2004 Sep; 13(3):269-70. PubMed ID: 15470542
    [No Abstract]   [Full Text] [Related]  

  • 54. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.
    Ishizawa T; Hasegawa K; Aoki T; Takahashi M; Inoue Y; Sano K; Imamura H; Sugawara Y; Kokudo N; Makuuchi M
    Gastroenterology; 2008 Jun; 134(7):1908-16. PubMed ID: 18549877
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contribution of endothelin-1 to the circulatory and renal abnormalities in patients with cirrhosis and portal hypertension.
    Helmy A; Hayes PC
    J Pediatr Gastroenterol Nutr; 2002 Aug; 35(2):139-43. PubMed ID: 12187287
    [No Abstract]   [Full Text] [Related]  

  • 56. Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment.
    Jaroszewicz J; Januszkiewicz M; Flisiak R; Rogalska M; Kalinowska A; Wierzbicka I
    Cytokine; 2008 Oct; 44(1):14-7. PubMed ID: 18656381
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Renal function in diffuse hepatopathies].
    León Castro J; Barranco Jiménez M
    Rev Clin Esp; 1971 May; 121(4):339-46. PubMed ID: 5563109
    [No Abstract]   [Full Text] [Related]  

  • 58. Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis.
    Sheng QS; Lang R; He Q; Yang YJ; Zhao DF; Chen DZ
    Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):46-9. PubMed ID: 19208514
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A study of steatorrhoea in cirrhosis of liver.
    Patney NL; Jasuja RK; Dwivedi KK; Prasad G; Kumar A
    J Assoc Physicians India; 1974 Jan; 22(1):25-9. PubMed ID: 4844726
    [No Abstract]   [Full Text] [Related]  

  • 60. The impact of cirrhosis and portal hypertension on mortality following colorectal surgery: a nationwide, population-based study.
    Nguyen GC; Correia AJ; Thuluvath PJ
    Dis Colon Rectum; 2009 Aug; 52(8):1367-74. PubMed ID: 19617746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.